JP2019534893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534893A5 JP2019534893A5 JP2019533297A JP2019533297A JP2019534893A5 JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5 JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- ipr
- optionally substituted
- cancer
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical class OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical group OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- -1 D-Dab Chemical compound 0.000 claims 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384132P | 2016-09-06 | 2016-09-06 | |
| US62/384,132 | 2016-09-06 | ||
| US201762505064P | 2017-05-11 | 2017-05-11 | |
| US62/505,064 | 2017-05-11 | ||
| PCT/US2017/050106 WO2018048806A1 (en) | 2016-09-06 | 2017-09-05 | Cxcr4 antagonists and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534893A JP2019534893A (ja) | 2019-12-05 |
| JP2019534893A5 true JP2019534893A5 (enExample) | 2020-08-20 |
| JP7100639B2 JP7100639B2 (ja) | 2022-07-13 |
Family
ID=61281979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533297A Active JP7100639B2 (ja) | 2016-09-06 | 2017-09-05 | Ｃｘｃｒ４アンタゴニストおよび使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10351601B2 (enExample) |
| EP (1) | EP3509612A4 (enExample) |
| JP (1) | JP7100639B2 (enExample) |
| CN (1) | CN109922818B (enExample) |
| CA (1) | CA3032885C (enExample) |
| WO (1) | WO2018048806A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| US10639379B2 (en) * | 2017-09-05 | 2020-05-05 | Mainline Biosciences Llc | High affinity CXCR4 selective binding conjugate and method for using the same |
| WO2019126796A1 (en) * | 2017-12-21 | 2019-06-27 | Mainline Biosciences Llc | Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same |
| EP4097120A4 (en) * | 2020-01-26 | 2024-05-01 | Mainline Biosciences (Shanghai) Co., Ltd. | ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF |
| US12486304B2 (en) * | 2022-02-11 | 2025-12-02 | C-Biomex Co., Ltd. | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof |
| GB2628421A (en) * | 2023-03-24 | 2024-09-25 | Syntherix Ltd | Peptides and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5811001A (en) * | 2000-05-09 | 2001-11-20 | Univ British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
| WO2004058243A1 (ja) * | 2002-12-26 | 2004-07-15 | Ajinomoto Co., Inc. | 肝癌発生・進展抑制剤 |
| CA2569807A1 (en) * | 2004-06-18 | 2005-12-29 | Ipf Pharmaceuticals Gmbh | Oligomeric peptides and their use for the treatment of hiv infections |
| CA2643744A1 (en) * | 2006-02-27 | 2007-08-30 | Technische Universitaet Muenchen | Cancer imaging and treatment |
| KR101319740B1 (ko) * | 2007-05-30 | 2013-10-17 | 일라이 릴리 앤드 캄파니 | 시클릭 펩티드 ｃｘｃｒ４ 길항제 |
| IT1397901B1 (it) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| SG11201400354PA (en) * | 2011-10-07 | 2014-09-26 | Polyphor Ag | Template -fixed peptidomimetics as inhibitors of fpr1 |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| CA2875733C (en) * | 2012-06-06 | 2019-09-10 | Polyphor Ag | Beta-hairpin peptidomimetics |
| US9790286B2 (en) * | 2013-01-02 | 2017-10-17 | Lucia Irene Gonzalez | Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis |
-
2017
- 2017-09-05 CN CN201780054250.5A patent/CN109922818B/zh not_active Expired - Fee Related
- 2017-09-05 CA CA3032885A patent/CA3032885C/en active Active
- 2017-09-05 US US15/695,862 patent/US10351601B2/en active Active
- 2017-09-05 EP EP17849397.9A patent/EP3509612A4/en not_active Withdrawn
- 2017-09-05 WO PCT/US2017/050106 patent/WO2018048806A1/en not_active Ceased
- 2017-09-05 JP JP2019533297A patent/JP7100639B2/ja active Active
-
2019
- 2019-06-04 US US16/431,657 patent/US10870681B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534893A5 (enExample) | ||
| JP6966678B2 (ja) | Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害 | |
| JP7307744B2 (ja) | がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体 | |
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| EP2958571B1 (en) | Dna hypomethylating agents for cancer therapy | |
| JP2016505586A5 (enExample) | ||
| JP2019527728A5 (enExample) | ||
| JP2018532690A5 (enExample) | ||
| JP2019503167A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2017525730A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2020532496A5 (enExample) | ||
| WO2011148083A4 (fr) | Peptide en tant que médicament, en particulier pour le traitement du cancer | |
| JP2017006120A5 (enExample) | ||
| JP2016506386A5 (enExample) | ||
| JP2019519512A5 (enExample) | ||
| JP2015520770A5 (enExample) | ||
| CN108697729A (zh) | 新型GLUT抑制剂rapaglutin及其用途 | |
| JP2019507764A5 (enExample) | ||
| JP2022174752A (ja) | Ｃｒｅｂｂｐ関連癌の治療法 | |
| JP2016531885A5 (enExample) | ||
| JP2011518168A5 (enExample) |